Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 82 Richmond Street East TORONTO ON M5C 1P1 |
Tel: | N/A |
Website: | https://www.pharmacielo.com |
IR: | See website |
Key People | ||
Marc Lustig Chairman of the Board, Chief Executive Officer | Ian D. Atacan Chief Financial Officer, Director | Andres Botero Chief Operating Officer |
Business Overview |
PharmaCielo Ltd. is a Canada-based company with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Company's all-natural cannabis into standardized, medicinal-grade oil extracts and related products. In Colombia, PharmaCielo Colombia is a licensed cultivator, producer, and distributor of both TetraHydroCannabinol (THC) and Cannabidiol (CBD) medical cannabis for use in Colombia, international export, and research purposes. Ubiquo is a knowledge management and medical consultation system that focuses on creating access to healthcare for Colombians. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate. Ubiquo is used as a communication tool. |
Financial Overview |
For the nine months ended 30 September 2023, Pharmacielo Ltd revenues decreased 66% to C$1.3M. Net loss applicable to common stockholders decreased 15% to C$9.9M. Revenues reflect Sale of Cannabis derivative products decrease of 68% to C$1.2M. Lower net loss reflects Salaries and wages decrease of 25% to C$3.1M (expense), Amortization and depreciation decrease of 78% to C$280K (expense). |
Employees: | 268 as of Dec 31, 2019 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $46.93M as of Sep 30, 2023 |
Annual revenue (TTM): | $2.81M as of Sep 30, 2023 |
EBITDA (TTM): | -$8.69M as of Sep 30, 2023 |
Net annual income (TTM): | -$12.82M as of Sep 30, 2023 |
Free cash flow (TTM): | -$5.19M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $16.77M as of Sep 30, 2023 |
Shares outstanding: | 169,745,157 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |